For research use only. Not for use in humans.

Domagrozumab (Anti-GDF8 / Myostatin)

Synonyms: MSTN， GDF8 Cat.No.A2826 Purity:99%

Domagrozumab (Anti-GDF8 / Myostatin) is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab has the potential to be used in research of duchenne muscular dystrophy (DMD). MW : 143.96 KD.

Quality Control

Batch: A282601 Purity: 99% Protein concentration: 8.86mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

Featured Inhibitors	Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933

Mechanism of Action

Description	Domagrozumab (Anti-GDF8 / Myostatin) is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab has the potential to be used in research of duchenne muscular dystrophy (DMD). MW : 143.96 KD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/29121992/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1629605-31-7
Molecular Weight	143.96
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07473440	COMPLETED		Exercise Adaptation; Aerobic Capacity; Athletic Performance; Combat Sports Training	Adiyaman University	2025-01-20
NCT07658261	COMPLETED		Overweight (BMI > 25); Obesity (BMI>30)	Arya Habibi	2024-05-01
NCT05573321	UNKNOWN		Muscle Hypotrophy	Ege University	2023-02-14
NCT03172403	TERMINATED		Cancer of Digestive System	Centre Hospitalier Universitaire de Saint Etienne	2018-08-02
NCT01958970	COMPLETED	Drug: PINTA 745\|Drug: Placebo	End Stage Renal Disease; Kidney Disease; Protein Energy Wasting	Pinta Biotherapeutics	2014-01	PHASE1; PHASE2
NCT01321320	COMPLETED		Intensive Care Unit Acquired Paresis; Muscle Wasting	Imperial College London	2011-04

(data from https://clinicaltrials.gov, updated on 2026-03-16)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.